Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
NPSP is one of my bio basket investments but I'm looking to add to it and make it a full investment position. On Friday the stock didn't move much given FBR Capital initiating coverage with an overweight rating. Company is transitioning to a profitable entity with minimal dilution risk. Gattex is currently showing solid sales and a 2nd drug, Natpara is in stage 3 clinical trials with possible FDA approval by end of this year. Additional information will be posted here.
Disclosure: The author is long NPSP.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
